NCT00241644View on ClinicalTrials.gov

Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

2,089

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Rotarix™

Two or Three doses, oral administration

BIOLOGICAL

Placebo

One or three doses, oral administration.

Trial Locations (13)

3

GSK Investigational Site, Bangwe, Blantyre

GSK Investigational Site, Limbe, Blantyre

GSK Investigational Site, Ndirande, Blantyre

GSK Investigational Site, Zingwanga, Blantyre

0250

GSK Investigational Site, Brits

Unknown

GSK Investigational Site, Diepkloof, Soweto

GSK Investigational Site, Diepsloot

GSK Investigational Site, Eldorado Park Ext 9, Soweto

GSK Investigational Site, Mamelodi

GSK Investigational Site, Mamelodi East

GSK Investigational Site, Shoshanguve

GSK Investigational Site, Tembisa

0118

GSK Investigational Site, Karenpark

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00241644 - Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants | Biotech Hunter | Biotech Hunter